<DOC>
	<DOC>NCT00143026</DOC>
	<brief_summary>This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations.</brief_summary>
	<brief_title>Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States</brief_title>
	<detailed_description>This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations. Treatment with carbidopa/levodopa/entacapone will be compared with treatment with standard formulation levodopa/carbidopa.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3 symptoms Motor functions must be regarded as nondisabling by the patient History, signs or symptoms suggesting the diagnosis of atypical or secondary parkinsonism History of dyskinesia Previous or current use of entacapone or tolcapone Unstable Parkinson's disease patients requiring/receiving regimens of levodopa Subjects taking levodopa/DDCI controlled release or extended release formulations</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson's disease, levodopa, motor fluctuations</keyword>
</DOC>